{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T17:14:04Z","timestamp":1763226844983},"reference-count":388,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Surgery"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.cpsurg.2020.100860","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T01:41:53Z","timestamp":1594690913000},"page":"100860","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Evolving Management of Peritoneal Surface Malignancies"],"prefix":"10.1016","volume":"58","author":[{"suffix":"IV","given":"John H.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Dan G.","family":"Blazer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose Godoy","family":"Calderon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor M.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin","family":"Eckhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad A.","family":"Al Efishat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deemantha G.","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason M.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Hayes-Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy B.","family":"Lautz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugwuji N.","family":"Maduekwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher W.","family":"Mangieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omeed","family":"Moaven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harveshp","family":"Mogal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perry","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos I.","family":"Votanopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"34","key":"10.1016\/j.cpsurg.2020.100860_bib0001","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.3748\/wjg.v22.i34.7692","article-title":"Pathophysiology of colorectal peritoneal carcinomatosis: role of the peritoneum","volume":"22","author":"Lemoine","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0002","first-page":"72","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection","volume":"7","author":"Esquivel","year":"2016","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0003","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0004","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1245\/ASO.2003.03.067","article-title":"Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis","volume":"10","author":"McQuellon","year":"2003","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.cpsurg.2020.100860_bib0005","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","article-title":"8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer","volume":"15","author":"Verwaal","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0006","first-page":"124","article-title":"Treatment principles for peritoneal surface malignancies","volume":"71","author":"Deraco","year":"2016","journal-title":"Minerva Chir"},{"issue":"20","key":"10.1016\/j.cpsurg.2020.100860_bib0007","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0008","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1245\/ASO.2006.03.079","article-title":"Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy","volume":"13","author":"Sugarbaker","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0009","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jss.2018.09.032","article-title":"Trends in outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"234","author":"Gani","year":"2019","journal-title":"J Surg Res"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0010","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1245\/s10434-013-3223-z","article-title":"Morbidity and mortality of cytoreduction with intraperitoneal chemotherapy: outcomes from the ACS NSQIP database","volume":"21","author":"Bartlett","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0011","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","article-title":"Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality","volume":"249","author":"Chua","year":"2009","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0012","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1245\/s10434-016-5692-3","article-title":"Current delivery of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery (CS\/HIPEC) and perioperative practices: an international survey of high-volume surgeons","volume":"24","author":"Maciver","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0013","first-page":"195","article-title":"Peritoneal metastases: challenges for the surgeon","volume":"70","author":"Baratti","year":"2015","journal-title":"Minerva Chir"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0014","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.ejso.2015.09.005","article-title":"Cytoreductive surgery with a hyperthermic intraperitoneal chemotherapy program: Safe after 40 cases, but only controlled after 140 cases","volume":"41","author":"Voron","year":"2015","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jso.21326","article-title":"Learning curve in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"100","author":"Moradi","year":"2009","journal-title":"J Surg Oncol"},{"issue":"13","key":"10.1016\/j.cpsurg.2020.100860_bib0016","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/bjs.9674","article-title":"Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei","volume":"101","author":"Kusamura","year":"2014","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0017","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00268-014-2801-y","article-title":"Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancy","volume":"39","author":"Kuijpers","year":"2015","journal-title":"World J Surg"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0018","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejso.2011.03.134","article-title":"Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer","volume":"37","author":"Cascales Campos","year":"2011","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0019","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jamcollsurg.2013.12.013","article-title":"Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients","volume":"218","author":"Levine","year":"2014","journal-title":"J Am Coll Surg"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0020","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1245\/s10434-013-3061-z","article-title":"Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States","volume":"21","author":"Turaga","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0021","doi-asserted-by":"crossref","first-page":"597","DOI":"10.14694\/EDBK_174794","article-title":"Clinical pathways and the patient perspective in the pursuit of value-based oncology care","volume":"37","author":"Ersek","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0022","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/14737167.8.1.43","article-title":"Patient-reported outcomes to evaluate surgery","volume":"8","author":"Avery","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0023","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/01.sla.0000094304.17672.6e","article-title":"The association of pretreatment health-related quality of life with surgical complications for patients undergoing open surgical resection for colorectal cancer","volume":"238","author":"Anthony","year":"2003","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0024","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/erp.10.15","article-title":"Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG","volume":"10","author":"Au","year":"2010","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1758834010395342","article-title":"Health-related quality of life and cancer clinical trials","volume":"3","author":"Osoba","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0026","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/EDBK_200383","article-title":"Implementation of patient-reported outcomes in routine medical care","volume":"38","author":"Basch","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0027","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1245\/s10434-006-9304-5","article-title":"Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis","volume":"14","author":"McQuellon","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.cpsurg.2020.100860_bib0028","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1586\/14737140.8.11.1809","article-title":"Intraperitoneal hyperthermic chemotherapy: an evolving paradigm for the treatment of peritoneal surface malignancies","volume":"8","author":"Stewart","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"issue":"8","key":"10.1016\/j.cpsurg.2020.100860_bib0029","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1200\/JCO.2007.13.3439","article-title":"The prognostic significance of patient-reported outcomes in cancer clinical trials","volume":"26","author":"Gotay","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0030","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/jso.23089","article-title":"Patient rated outcomes and survivorship following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS\u202f+\u202fHIPEC)","volume":"106","author":"Duckworth","year":"2012","journal-title":"J Surg Oncol"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0031","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ejso.2010.09.004","article-title":"Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei","volume":"36","author":"Alves","year":"2010","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0032","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1245\/s10434-007-9678-z","article-title":"Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin","volume":"15","author":"McQuellon","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0033","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1245\/s10434-019-07425-5","article-title":"Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on quality of life in patients with peritoneal mesothelioma","volume":"27","author":"Ali","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.cpsurg.2020.100860_bib0034","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1245\/s10434-016-5231-2","article-title":"Impact of major complications on patients' quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"23","author":"Hamilton","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.suronc.2014.10.002","article-title":"Quality of life after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy for peritoneal carcinomatosis: A systematic review and meta-analysis","volume":"23","author":"Shan","year":"2014","journal-title":"Surg Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0036","first-page":"488","article-title":"Quality of life after cytoreductive surgery and HIPEC: A single centre prospective study","volume":"23","author":"Kopanakis","year":"2018","journal-title":"J BUON"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0037","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ejso.2016.03.004","article-title":"No impact on long-term survival of prolonged ICU stay and re-admission for patients undergoing cytoreductive surgery with HIPEC","volume":"42","author":"Wallet","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0038","first-page":"30444","article-title":"Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer","volume":"19","author":"Koole","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0039","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1245\/s10434-019-07385-w","article-title":"Impairments in bowel function, social function and quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"27","author":"Bayat","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0040","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/000313481708300630","article-title":"The impact of early recurrence on quality of life after cytoreduction with HIPEC","volume":"83","author":"Hinkle","year":"2017","journal-title":"Am Surg"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0041","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1006\/jsre.2002.6549","article-title":"Health-related quality of life and postoperative length of stay for patients with colorectal cancer","volume":"108","author":"Holloway","year":"2002","journal-title":"J Surg Res"},{"issue":"11","key":"10.1016\/j.cpsurg.2020.100860_bib0042","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1245\/s10434-013-3049-8","article-title":"Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status","volume":"20","author":"Ihemelandu","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.cpsurg.2020.100860_bib0043","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1245\/s10434-016-5547-y","article-title":"Quality-of- life evaluation after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"23","author":"Dodson","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0044","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejso.2016.09.015","article-title":"Oxaliplatin vs Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis","volume":"43","author":"Leung","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0045","first-page":"772","article-title":"Health- related quality of life after cytoreductive surgery \/HIPEC for mucinous appendiceal cancer: results of a multicenter randomized trial comparing oxaliplatin and mitomycin","volume":"27","author":"Moaven","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0046","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1245\/s10434-019-08106-z","article-title":"Health- related quality of life after cytoreductive surgery \/HIPEC for mucinous appendiceal cancer: results of a multicenter randomized trial comparing oxaliplatin and mitomycin","volume":"27","author":"Tun","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0047","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3390\/jcm7120567","article-title":"Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer","volume":"7","author":"Yurttas","year":"2018","journal-title":"J Clin Med"},{"issue":"30","key":"10.1016\/j.cpsurg.2020.100860_bib0048","doi-asserted-by":"crossref","first-page":"e16467","DOI":"10.1097\/MD.0000000000016467","article-title":"Impact of anesthesia management during cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for the treatment of colorectal peritoneal carcinomatosis on intra- and postoperative outcomes: A systematic review protocol","volume":"98","author":"Idrissi","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0049","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/jamasurg.2017.2865","article-title":"Association of fluid administration with morbidity in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"152","author":"Eng","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0050","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1477-7819-12-136","article-title":"Anaesthesia in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: retrospective analysis of a single centre three-year experience","volume":"12","author":"Kajdi","year":"2014","journal-title":"World J Surg Oncol"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0051","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2044.2007.05380.x","article-title":"Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"63","author":"Schmidt","year":"2008","journal-title":"Anaesthesia"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0052","doi-asserted-by":"crossref","first-page":"972","DOI":"10.4103\/ija.IJA_765_19","article-title":"Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)","volume":"63","author":"Solanki","year":"2019","journal-title":"Indian J Anaesth"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0053","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s00464-018-6352-4","article-title":"A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis","volume":"33","author":"Arjona-Sanchez","year":"2019","journal-title":"Surg Endosc"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0054","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/SLA.0b013e31820784df","article-title":"Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with limited peritoneal surface malignancies: feasibility, morbidity and outcome in an early experience","volume":"253","author":"Esquivel","year":"2011","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0055","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11701-018-0820-7","article-title":"Robotic-assisted cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)","volume":"13","author":"Gabriel","year":"2019","journal-title":"J Robot Surg"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0056","unstructured":"Cancer, W.H.O.I.A.f.R.o. Global Cancer Observatory. [cited 2019 December 20, 2019]."},{"issue":"16","key":"10.1016\/j.cpsurg.2020.100860_bib0057","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","article-title":"Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study","volume":"22","author":"Glehen","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0058","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/1097-0142(19840115)53:2<360::AID-CNCR2820530232>3.0.CO;2-U","article-title":"Adenocarcinoma of the proximal colon. Sites of initial dissemination and patterns of recurrence following surgery alone","volume":"53","author":"Russell","year":"1984","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0059","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","article-title":"Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study","volume":"88","author":"Sadeghi","year":"2000","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.cpsurg.2020.100860_bib0060","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1634\/theoncologist.11-9-981","article-title":"Therapy for metastatic colorectal cancer","volume":"11","author":"Goldberg","year":"2006","journal-title":"Oncologist"},{"issue":"21","key":"10.1016\/j.cpsurg.2020.100860_bib0061","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0062","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12885-016-2158-8","article-title":"Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice","volume":"16","author":"Razenberg","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0063","doi-asserted-by":"crossref","first-page":"18632","DOI":"10.1038\/srep18632","article-title":"Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin","volume":"5","author":"van Oudheusden","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0064","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","article-title":"Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841","volume":"30","author":"Franko","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0065","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00000658-199502000-00002","article-title":"Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0066","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/000313480006600607","article-title":"Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin","volume":"66","author":"Loggie","year":"2000","journal-title":"Am Surg"},{"issue":"10","key":"10.1016\/j.cpsurg.2020.100860_sbref0067","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/BF02236627","article-title":"Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs","volume":"43","author":"Pestieau","year":"2000","journal-title":"delayed management. Dis Colon Rectum"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0068","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9","article-title":"Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy","volume":"92","author":"Elias","year":"2001","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0069","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1245\/ASO.2004.05.009","article-title":"Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma","volume":"11","author":"Shen","year":"2004","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.cpsurg.2020.100860_bib0070","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/DCR.0000000000000149","article-title":"Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients","volume":"57","author":"Baratti","year":"2014","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0071","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin","volume":"27","author":"Elias","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.cpsurg.2020.100860_bib0072","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1002\/cncr.25116","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion vs systemic chemotherapy alone for colorectal peritoneal carcinomatosis","volume":"116","author":"Franko","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0073","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejso.2010.01.006","article-title":"Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy","volume":"36","author":"Elias","year":"2010","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0074","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1245\/s10434-008-0234-2","article-title":"Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis","volume":"16","author":"Koh","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00261-007-9211-7","article-title":"Staging of peritoneal carcinomatosis: enhanced CT vs. PET\/CT","volume":"33","author":"Dromain","year":"2008","journal-title":"Abdom Imaging"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0076","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1245\/s10434-006-9185-7","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement","volume":"14","author":"Esquivel","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"10.1016\/j.cpsurg.2020.100860_bib0077","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy vs systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0078","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2015.09.017","article-title":"Cytoreductive surgery and intraperitoneal chemotherapy vs systemic chemotherapy for colorectal peritoneal metastases: A randomised trial","volume":"53","author":"Cashin","year":"2016","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0079","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/SLA.0b013e3181d9765d","article-title":"A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix","volume":"251","author":"Elias","year":"2010","journal-title":"Ann Surg"},{"issue":"18 Suppl","key":"10.1016\/j.cpsurg.2020.100860_bib0080","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503","article-title":"A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7","volume":"36","author":"Quenet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.cpsurg.2020.100860_bib0081","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2018.36.15_suppl.3531","article-title":"BIG-RENAPE and PRODIGE. Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP- NTC01226394)","volume":"36","author":"Goere","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0082","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.surg.2015.01.021","article-title":"Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands","volume":"157","author":"van Oudheusden","year":"2015","journal-title":"Surgery"},{"issue":"10","key":"10.1016\/j.cpsurg.2020.100860_bib0083","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0084","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s12885-015-1430-7","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial","volume":"15","author":"Klaver","year":"2015","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0085","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/jso.23749","article-title":"Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis","volume":"110","author":"Ahmed","year":"2014","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0086","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF00257130","article-title":"Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids","volume":"13","author":"Nederman","year":"1984","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0087","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0959-8049(97)00370-5","article-title":"Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines","volume":"34","author":"van de Vaart","year":"1998","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0088","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/00365521.2012.640825","article-title":"Surgery for colorectal peritoneal carcinomatosis","volume":"47","author":"Chua","year":"2012","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0089","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF02236899","article-title":"Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies","volume":"41","author":"Connor","year":"1998","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clcc.2018.11.007","article-title":"Review: pathology and its clinical relevance of mucinous appendiceal neoplasms and pseudomyxoma peritonei","volume":"18","author":"Legue","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0091","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.soc.2018.02.007","article-title":"Peritoneal metastases from appendiceal cancer","volume":"27","author":"Votanopoulos","year":"2018","journal-title":"Surg Oncol Clin N Am"},{"issue":"10","key":"10.1016\/j.cpsurg.2020.100860_bib0092","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/jclinpath-2012-200843","article-title":"Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases","volume":"65","author":"Carr","year":"2012","journal-title":"J Clin Pathol"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0093","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/01.pas.0000202039.74837.7d","article-title":"Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review","volume":"30","author":"Bradley","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.cpsurg.2020.100860_bib0094","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/bjs.8739","article-title":"Classification of and cytoreductive surgery for low-grade appendiceal mucinous neoplasms","volume":"99","author":"McDonald","year":"2012","journal-title":"Br J Surg"},{"issue":"Suppl 1","key":"10.1016\/j.cpsurg.2020.100860_bib0095","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1038\/modpathol.2014.129","article-title":"Mucinous epithelial neoplasms of the appendix and pseudomyxoma peritonei","volume":"28","author":"Misdraji","year":"2015","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0096","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0000000000000535","article-title":"A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified delphi process","volume":"40","author":"Carr","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0097","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/PAP.0000000000000178","article-title":"An update on the diagnosis, grading, and staging of appendiceal mucinous neoplasms","volume":"25","author":"Valasek","year":"2018","journal-title":"Adv Anat Pathol"},{"issue":"9","key":"10.1016\/j.cpsurg.2020.100860_bib0098","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1245\/s10434-017-5938-8","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for moderately and poorly differentiated appendiceal adenocarcinoma: survival outcomes and patient selection","volume":"24","author":"Grotz","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.cpsurg.2020.100860_bib0099","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1245\/s10434-018-6488-4","article-title":"Management of mucinous appendiceal tumors","volume":"25","author":"Choudry","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0100","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1245\/s10434-012-2238-1","article-title":"Importance of histologic subtype in the staging of appendiceal tumors","volume":"19","author":"Turaga","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0101","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0102","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ijc.1473","article-title":"Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden","volume":"94","author":"Hemminki","year":"2001","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.cpsurg.2020.100860_bib0103","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/PAS.0b013e31817f1816","article-title":"Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix","volume":"32","author":"Tang","year":"2008","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0104","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00268-011-1296-z","article-title":"Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center","volume":"36","author":"Norlen","year":"2012","journal-title":"World J Surg"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0105","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00330-012-2615-y","article-title":"Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases","volume":"23","author":"Bhosale","year":"2013","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0106","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000371817","article-title":"Updating the surgical management of peritoneal carcinomatosis in patients with neuroendocrine tumors","volume":"101","author":"de Mestier","year":"2015","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0107","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ando.2019.04.006","article-title":"Digestive system mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN)","volume":"80","author":"de Mestier","year":"2019","journal-title":"Ann Endocrinol (Paris)"},{"issue":"8","key":"10.1016\/j.cpsurg.2020.100860_bib0108","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1245\/s10434-019-07447-z","article-title":"Discordant diagnostic terminology and pathologic grading of primary appendiceal mucinous neoplasms reviewed at a high-volume center","volume":"26","author":"Choudry","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.cpsurg.2020.100860_bib0109","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41379-019-0216-x","article-title":"Knowledge gaps in the appendix: a multi-institutional study from seven academic centers","volume":"32","author":"Arnold","year":"2019","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0110","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/s41379-018-0003-0","article-title":"Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas","volume":"31","author":"Johncilla","year":"2018","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0111","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/gm559","article-title":"Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin","volume":"6","author":"Alakus","year":"2014","journal-title":"Genome Med"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0112","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jamcollsurg.2011.12.028","article-title":"Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes","volume":"214","author":"Levine","year":"2012","journal-title":"J Am Coll Surg"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0113","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jamcollsurg.2015.12.012","article-title":"Prognostic molecular subtypes of low-grade cancer of the appendix","volume":"222","author":"Levine","year":"2016","journal-title":"J Am Coll Surg"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0114","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1245\/s10434-019-07879-7","article-title":"Molecular and genetic markers in appendiceal mucinous tumors: a systematic review","volume":"27","author":"Stein","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0115","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00261-008-9464-9","article-title":"64-Section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings","volume":"35","author":"Marin","year":"2010","journal-title":"Abdom Imaging"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0116","first-page":"2363","article-title":"Preoperative assessment of peritoneal carcinomatosis in patients undergoing hyperthermic intraperitoneal chemotherapy following cytoreductive surgery","volume":"34","author":"Pasqual","year":"2014","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40644-018-0187-z","article-title":"Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases","volume":"19","author":"Dresen","year":"2019","journal-title":"Cancer Imaging"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0118","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s11605-008-0774-6","article-title":"Adenocarcinoma of the appendix is rarely detected by colonoscopy","volume":"13","author":"Trivedi","year":"2009","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0119","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jamcollsurg.2017.12.027","article-title":"A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors","volume":"226","author":"Levine","year":"2018","journal-title":"J Am Coll Surg"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0120","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/DCR.0000000000001530","article-title":"The American Society of Colon and Rectal Surgeons, Clinical Practice Guidelines for the management of appendiceal neoplasms","volume":"62","author":"Glasgow","year":"2019","journal-title":"Dis Colon Rectum"},{"issue":"7","key":"10.1016\/j.cpsurg.2020.100860_bib0121","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1008215730767","article-title":"Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center","volume":"8","author":"Janson","year":"1997","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.cpsurg.2020.100860_bib0122","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ejso.2010.05.024","article-title":"Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC","volume":"36","author":"Ross","year":"2010","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0123","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1245\/s10434-012-2627-5","article-title":"Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin","volume":"20","author":"Wagner","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0124","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejso.2013.12.021","article-title":"Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients","volume":"40","author":"Taflampas","year":"2014","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0125","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/01.sla.0000231705.40081.1a","article-title":"Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"245","author":"Smeenk","year":"2007","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0126","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1245\/s10434-015-4838-z","article-title":"Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in patients with high-grade, high-volume disseminated mucinous appendiceal neoplasms","volume":"23","author":"Polanco","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0127","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s10434-006-9708-2","article-title":"Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy","volume":"13","author":"Stewart","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.cpsurg.2020.100860_bib0128","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1245\/s10434-013-3053-z","article-title":"Outcomes of Cytoreductive Surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality","volume":"20","author":"Votanopoulos","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0129","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/bjs.4862","article-title":"Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei","volume":"92","author":"Bryant","year":"2005","journal-title":"Br J Surg"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0130","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jamcollsurg.2012.04.023","article-title":"Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy","volume":"215","author":"Votanopoulos","year":"2012","journal-title":"J Am Coll Surg"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0131","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1245\/s10434-015-4995-0","volume":"23","author":"Ihemelandu","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.cpsurg.2020.100860_bib0132","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jso.23547","article-title":"Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"109","author":"Blackham","year":"2014","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0133","first-page":"1","article-title":"Systemic chemotherapy prior to cytoreductive surgery and HIPEC for carcinomatosis from appendix cancer: impact on perioperative outcomes and short-term survival","volume":"2012","author":"Bijelic","year":"2012","journal-title":"Gastroenterol Res Pract"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0134","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1245\/s10434-011-1840-y","article-title":"The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS\/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis","volume":"19","author":"El Halabi","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0135","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","article-title":"The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American Neuroendocrine Tumor Society","volume":"46","author":"Howe","year":"2017","journal-title":"Pancreas"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0136","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jss.2015.03.051","article-title":"Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"196","author":"Randle","year":"2015","journal-title":"J Surg Res"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0137","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1245\/s10434-013-3469-5","article-title":"Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: an emerging treatment option for advanced goblet cell tumors of the appendix","volume":"21","author":"McConnell","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0138","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1245\/s10434-019-08143-8","article-title":"Model of patient-specific immune-enhanced organoids for immunotherapy screening: feasibility study","volume":"27","author":"Votanopoulos","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0139","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0140","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0141","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.annepidem.2017.04.001","article-title":"Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis","volume":"27","author":"Mezei","year":"2017","journal-title":"Ann Epidemiol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0142","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification","volume":"11","author":"Galateau-Salle","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0143","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/cyt.12738","article-title":"Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions","volume":"30","author":"Onder","year":"2019","journal-title":"Cytopathology"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0144","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1245\/s10434-018-07153-2","article-title":"Well- differentiated papillary mesothelioma of the peritoneum: a retrospective study from the RENAPE observational registry","volume":"26","author":"Vogin","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0145","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/PAT.0b013e3283631cce","article-title":"Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy","volume":"45","author":"Lee","year":"2013","journal-title":"Pathology"},{"issue":"10","key":"10.1016\/j.cpsurg.2020.100860_bib0146","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1245\/s10434-007-9475-8","article-title":"Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC)","volume":"14","author":"Baratti","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"14","key":"10.1016\/j.cpsurg.2020.100860_bib0147","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin vs cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0148","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program","volume":"7","author":"Janne","year":"2005","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0149","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","article-title":"Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent","volume":"64","author":"Carteni","year":"2009","journal-title":"Lung Cancer"},{"issue":"21","key":"10.1016\/j.cpsurg.2020.100860_bib0150","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1200\/JCO.2007.15.2868","article-title":"Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial","volume":"26","author":"Simon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10026","key":"10.1016\/j.cpsurg.2020.100860_bib0151","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.cpsurg.2020.100860_bib0152","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s00595-005-2991-x","article-title":"Parasternal lymph node metastasis of malignant peritoneal mesothelioma: report of a case","volume":"35","author":"Ito","year":"2005","journal-title":"Surg Today"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0153","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1245\/s10434-019-07409-5","article-title":"50 patients with malignant mesothelioma of both the pleura and peritoneum: a single-institution experience","volume":"27","author":"Letica-Kriegel","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0154","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/erp.10.15","article-title":"Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG","volume":"10","author":"Au","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0155","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/bjs.10989","article-title":"Diffusion-weighted MRI assessment of the peritoneal cancer index before cytoreductive surgery","volume":"106","author":"van 't Sant","year":"2019","journal-title":"Br J Surg"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0156","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jso.23878","article-title":"Comparison between MRI and CT in prediction of peritoneal carcinomatosis index (PCI) in patients undergoing cytoreductive surgery in relation to the experience of the radiologist","volume":"111","author":"Torkzad","year":"2015","journal-title":"J Surg Oncol"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0157","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1245\/s10434-014-4041-7","article-title":"Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures","volume":"22","author":"Low","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0158","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/bjs5.50193","article-title":"Role of diagnostic laparoscopy in patients with suspicion of colorectal peritoneal metastases to evaluate suitability for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"3","author":"Hentzen","year":"2019","journal-title":"BJS Open"},{"issue":"8","key":"10.1016\/j.cpsurg.2020.100860_bib0159","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/jso.23924","article-title":"Incorporation of diagnostic laparoscopy in the management algorithm for patients with peritoneal metastases: A multi-institutional analysis","volume":"111","author":"Tabrizian","year":"2015","journal-title":"J Surg Oncol"},{"issue":"9","key":"10.1016\/j.cpsurg.2020.100860_bib0160","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1002\/cncr.10492","article-title":"TNM residual tumor classification revisited","volume":"94","author":"Wittekind","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0161","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12957-016-0996-0","article-title":"Early identification of DPAM in at-risk low-grade appendiceal mucinous neoplasm patients: a new approach to surveillance for peritoneal metastasis","volume":"14","author":"Foster","year":"2016","journal-title":"World J Surg Oncol"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0162","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1055-3207(03)00037-1","article-title":"Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma","volume":"12","author":"Glehen","year":"2003","journal-title":"Surg Oncol Clin N Am"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0163","doi-asserted-by":"crossref","first-page":"e186847","DOI":"10.1001\/jamanetworkopen.2018.6847","article-title":"Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures","volume":"2","author":"Foster","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0164","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","article-title":"Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma","volume":"153","author":"Alexander","year":"2013","journal-title":"Surgery"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0165","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1245\/s10434-014-3803-6","article-title":"Current trends in the management of malignant peritoneal mesothelioma","volume":"21","author":"Miura","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"36","key":"10.1016\/j.cpsurg.2020.100860_bib0166","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.cpsurg.2020.100860_bib0167","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1245\/s10434-018-6499-1","article-title":"Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival","volume":"25","author":"Verma","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0168","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","article-title":"Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study","volume":"65","author":"Kepenekian","year":"2016","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0169","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis","volume":"22","author":"Helm","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.cpsurg.2020.100860_bib0170","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1245\/s10434-017-6106-x","article-title":"Recurrence of optimally treated malignant peritoneal mesothelioma with cytoreduction and heated intraperitoneal chemotherapy","volume":"24","author":"Heller","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0171","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.cpsurg.2020.100860_bib0172","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","article-title":"Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival","volume":"43","author":"Sugarbaker","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0173","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0174","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0175","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0176","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jtho.2016.12.019","article-title":"BAP1 Is altered by copy number loss, mutation, and\/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas","volume":"12","author":"Leblay","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0177","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12967-015-0485-1","article-title":"BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma","volume":"13","author":"Alakus","year":"2015","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0178","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","volume":"29","author":"Singhi","year":"2016","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0179","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/his.13392","article-title":"The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma","volume":"72","author":"Chou","year":"2018","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0180","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1245\/s10434-008-0206-6","article-title":"Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma","volume":"16","author":"Foster","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0181","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1477-7819-8-88","article-title":"Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma","volume":"8","author":"Foster","year":"2010","journal-title":"World J Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0182","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0183","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc.2016.113","article-title":"The disparate origins of ovarian cancers: pathogenesis and prevention strategies","volume":"17","author":"Karnezis","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0184","doi-asserted-by":"crossref","first-page":"421","DOI":"10.14740\/wjon848w","article-title":"Double pathology: malignant epithelial ovarian tumor and germ cell tumor (Choriocarcinoma), a rare coexistence","volume":"6","author":"Shanmugasundaram","year":"2015","journal-title":"World J Oncol"},{"issue":"10177","key":"10.1016\/j.cpsurg.2020.100860_bib0185","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cpsurg.2020.100860_bib0186","first-page":"19","article-title":"Is it the right moment to include hyperthermic intraperitoneal chemotherapy as standard in ovarian cancer management? A reappraisal","volume":"23","author":"Samartzis","year":"2018","journal-title":"J buon"},{"issue":"9","key":"10.1016\/j.cpsurg.2020.100860_bib0187","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/cancers10090296","article-title":"Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer","volume":"10","author":"Jewell","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"26","key":"10.1016\/j.cpsurg.2020.100860_bib0188","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide vs intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0189","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.cpsurg.2020.100860_bib0190","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.cpsurg.2020.100860_bib0191","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1200\/JCO.2015.61.4776","article-title":"Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer","volume":"33","author":"Wright","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0192","first-page":"256","article-title":"Clinical delivery system for intraperitoneal hyperthermic chemotherapy","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0193","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/PPO.0b013e3181a58e74","article-title":"Technology of hyperthermic intraperitoneal chemotherapy in the United States, Europe, China, Japan, and Korea","volume":"15","author":"Esquivel","year":"2009","journal-title":"Cancer J"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0194","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.cpsurg.2020.100860_bib0195","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1245\/s10434-017-6151-5","article-title":"Comment on: Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study","volume":"24","author":"Batista","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0196","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/02656736.2017.1283066","article-title":"Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer","volume":"33","author":"Cowan","year":"2017","journal-title":"Int J Hyperthermia"},{"issue":"15_suppl","key":"10.1016\/j.cpsurg.2020.100860_bib0197","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1200\/JCO.2017.35.15_suppl.5519","article-title":"A phase 3 trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer","volume":"35","author":"Driel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.cpsurg.2020.100860_bib0198","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1200\/JCO.2017.35.15_suppl.5520","article-title":"Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer","volume":"35","author":"Lim","year":"2017","journal-title":"J Clin Oncol,"},{"issue":"S24","key":"10.1016\/j.cpsurg.2020.100860_bib0199","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1002\/cncr.32496","article-title":"Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer","volume":"125","author":"Vergote","year":"2019","journal-title":"Cancer"},{"issue":"S24","key":"10.1016\/j.cpsurg.2020.100860_bib0200","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1002\/cncr.32505","article-title":"Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on","volume":"125","author":"Koole","year":"2019","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0201","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00404-018-4908-0","article-title":"Is there a role for HIPEC in ovarian cancer?","volume":"298","author":"Harter","year":"2018","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0202","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13048-019-0509-1","article-title":"The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis","volume":"12","author":"Zhang","year":"2019","journal-title":"J Ovarian Res"},{"issue":"50","key":"10.1016\/j.cpsurg.2020.100860_bib0203","doi-asserted-by":"crossref","first-page":"e18355","DOI":"10.1097\/MD.0000000000018355","article-title":"Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: A systematic review and meta-analysis","volume":"98","author":"Kim","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0204","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1245\/s10434-015-4991-4","article-title":"Hyperthermic intraperitoneal chemotherapy after secondary cytoreduction in epithelial ovarian cancer: a single-center comparative analysis","volume":"23","author":"Baiocchi","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0205","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","article-title":"Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up","volume":"127","author":"Fagotti","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0206","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/ijgc-00009577-200503000-00008","article-title":"Intraperitoneal hyperthermic chemotherapy in ovarian cancer","volume":"15","author":"Gori","year":"2005","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0207","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jso.21448","article-title":"Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer","volume":"101","author":"Kim","year":"2010","journal-title":"J Surg Oncol"},{"issue":"11","key":"10.1016\/j.cpsurg.2020.100860_bib0208","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1245\/s10434-014-3693-7","article-title":"Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study","volume":"21","author":"Le Brun","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0209","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00280-017-3376-8","article-title":"Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience","volume":"80","author":"Mendivil","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"10.1016\/j.cpsurg.2020.100860_bib0210","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12094-009-0438-3","article-title":"The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer","volume":"11","author":"Munoz-Casares","year":"2009","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0211","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2004.05.044","article-title":"Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer","volume":"94","author":"Ryu","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0212","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jso.23688","article-title":"Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study","volume":"110","author":"Safra","year":"2014","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0213","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1754-9493-6-12","article-title":"Does hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patients","volume":"6","author":"Warschkow","year":"2012","journal-title":"Patient Saf Surg"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0214","unstructured":"Chicago Consensus Working, G., The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. Cancer, 2020;27(6):1780-1787."},{"issue":"8","key":"10.1016\/j.cpsurg.2020.100860_bib0215","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11912-019-0820-4","article-title":"Updates on Management of Gastric Cancer","volume":"21","author":"Johnston","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"10060","key":"10.1016\/j.cpsurg.2020.100860_bib0216","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/S0140-6736(16)30354-3","article-title":"Gastric cancer","volume":"388","author":"Van Cutsem","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0217","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ijc.28373","article-title":"Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors","volume":"134","author":"Thomassen","year":"2014","journal-title":"Int J Cancer"},{"issue":"32","key":"10.1016\/j.cpsurg.2020.100860_bib0218","doi-asserted-by":"crossref","first-page":"52307","DOI":"10.18632\/oncotarget.10740","article-title":"Metastatic spread in patients with gastric cancer","volume":"7","author":"Riihimaki","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0219","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.amjsurg.2005.10.015","article-title":"Selection of patients with gastric adenocarcinoma for laparoscopic staging","volume":"191","author":"Sarela","year":"2006","journal-title":"Am J Surg"},{"issue":"13","key":"10.1016\/j.cpsurg.2020.100860_bib0220","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1245\/s10434-016-5409-7","article-title":"Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer","volume":"23","author":"Ikoma","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0221","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3322\/caac.21440","article-title":"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States","volume":"68","author":"Islami","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"suppl 5","key":"10.1016\/j.cpsurg.2020.100860_bib0222","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0223","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy vs surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0224","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"Al-Batran","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10184","key":"10.1016\/j.cpsurg.2020.100860_bib0225","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0226","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3322\/caac.21395","article-title":"Colorectal cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.cpsurg.2020.100860_bib0227","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/jso.24405","article-title":"Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration","volume":"114","author":"Chang","year":"2016","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0228","first-page":"Cd004064","article-title":"Chemotherapy for advanced gastric cancer","volume":"8","author":"Wagner","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"9742","key":"10.1016\/j.cpsurg.2020.100860_bib0229","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy vs chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0230","doi-asserted-by":"crossref","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0231","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1470-2045(18)30791-5","article-title":"Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Fuchs","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9911","key":"10.1016\/j.cpsurg.2020.100860_bib0232","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0233","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy plus chemotherapy vs chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial","volume":"17","author":"Fujitani","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0234","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000658-198807000-00005","article-title":"Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding","volume":"208","author":"Fujimoto","year":"1988","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0235","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/1097-0142(19880115)61:2<232::AID-CNCR2820610205>3.0.CO;2-U","article-title":"Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C","volume":"61","author":"Koga","year":"1988","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0236","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jso.24087","article-title":"Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases","volume":"113","author":"Shiozaki","year":"2016","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0237","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0238","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s10120-019-00969-1","article-title":"The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis","volume":"22","author":"Rau","year":"2019","journal-title":"Gastric Cancer"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0239","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1002\/cam4.2204","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: A retrospective cooperative Central-Eastern European study","volume":"8","author":"Yarema","year":"2019","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.cpsurg.2020.100860_bib0240","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1245\/s10434-019-07450-4","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP)","volume":"26","author":"Manzanedo","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0241","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.gassur.2003.12.014","article-title":"Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer","volume":"8","author":"Hall","year":"2004","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0242","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1477-7800-2-3","article-title":"Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer","volume":"2","author":"Harmon","year":"2005","journal-title":"Int Semin Surg Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0243","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4251\/wjgo.v2.i2.85","article-title":"Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer","volume":"2","author":"Yonemura","year":"2010","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0244","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/bjs.4695","article-title":"Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion","volume":"92","author":"Yonemura","year":"2005","journal-title":"Br J Surg"},{"issue":"9","key":"10.1016\/j.cpsurg.2020.100860_bib0245","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0246","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.ejso.2018.08.009","article-title":"Colorectal peritoneal carcinomatosis: What is the future of HIPEC?","volume":"44","author":"Quenet","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0247","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"10.1016\/j.cpsurg.2020.100860_bib0248","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.cpsurg.2020.100860_bib0249","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1245\/s10434-007-9487-4","article-title":"A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer","volume":"14","author":"Yan","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0250","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9","article-title":"Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma","volume":"85","author":"Fujimoto","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0251","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","article-title":"The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer","volume":"79","author":"Desiderio","year":"2017","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.cpsurg.2020.100860_bib0252","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1001\/jamasurg.2019.0153","article-title":"Combined surgery and extensive intraoperative peritoneal lavage vs surgery alone for treatment of locally advanced gastric cancer: The SEIPLUS Randomized Clinical Trial","volume":"154","author":"Guo","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0253","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/jamasurg.2019.0154","article-title":"Extensive intraoperative peritoneal lavage to prevent metastases from gastric cancer: the elegance of simplicity","volume":"154","author":"Levine","year":"2019","journal-title":"JAMA Surg"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0254","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1245\/s10434-018-07140-7","article-title":"Laparoscopic hyperthermic intraperitoneal chemotherapy is safe for patients with peritoneal metastases from gastric cancer and may lead to gastrectomy","volume":"26","author":"Newhook","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0255","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3748\/wjg.v22.i3.1114","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer","volume":"22","author":"Seshadri","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.cpsurg.2020.100860_bib0256","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1245\/s10434-012-2360-0","article-title":"Laparoscopic hyperthermic intraperitoneal chemotherapy: indications, aims, and results: a systematic review of the literature","volume":"19","author":"Facchiano","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.cpsurg.2020.100860_bib0257","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jamasurg.2019.1698","article-title":"Survival outcomes among patients with gastric adenocarcinoma who received hyperthermic intraperitoneal chemotherapy with cytoreductive surgery","volume":"154","author":"Kimbrough","year":"2019","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0258","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10120-019-00978-0","article-title":"Peritoneal metastasis in gastric cancer: results from the German database","volume":"23","author":"Rau","year":"2020","journal-title":"Gastric Cancer"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0259","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/02656736.2017.1283065","article-title":"Current status and future prospects of clinical trials on CRS\u202f+\u202fHIPEC for gastric cancer peritoneal metastases","volume":"33","author":"Ji","year":"2017","journal-title":"Int J Hyperthermia"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0260","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.annepidem.2008.10.004","article-title":"The epidemiology and pathogenesis of neoplasia in the small intestine","volume":"19","author":"Schottenfeld","year":"2009","journal-title":"Ann Epidemiol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0261","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0262","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.dld.2013.04.013","article-title":"Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment","volume":"46","author":"Aparicio","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0263","first-page":"2912361","article-title":"Prognostic factors and survival time in patients with small bowel tumors: a retrospective observational study","volume":"2019","author":"Taghipour Zahir","year":"2019","journal-title":"Int J Surg Oncol"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0264","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1245\/s10434-018-6369-x","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal metastases from a small bowel adenocarcinoma: multi-institutional experience","volume":"25","author":"Liu","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_sbref0265","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archsurg.137.5.564","article-title":"Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management","volume":"137","author":"Talamonti","year":"2002","journal-title":"Arch Surg"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0266","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cncr.20404","article-title":"Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients","volume":"101","author":"Dabaja","year":"2004","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0267","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1177\/000313481307900629","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma","volume":"79","author":"Sun","year":"2013","journal-title":"Am Surg"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0268","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1245\/s10434-015-5056-4","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from small bowel malignancy: results from a single specialized center","volume":"23","author":"Liu","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0269","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejso.2018.11.012","article-title":"Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study","volume":"45","author":"Rompteaux","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"9-10","key":"10.1016\/j.cpsurg.2020.100860_bib0270","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/0284186X.2016.1182211","article-title":"Trends in incidence, treatment and survival of small bowel adenocarcinomas between 1999 and 2013: a population-based study in The Netherlands","volume":"55","author":"Legue","year":"2016","journal-title":"Acta Oncol"},{"issue":"10","key":"10.1016\/j.cpsurg.2020.100860_bib0271","first-page":"5737","article-title":"Recurrence and survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for small bowel adenocarcinoma","volume":"37","author":"Saxena","year":"2017","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0272","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/jso.21315","article-title":"Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma","volume":"100","author":"Chua","year":"2009","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0273","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/ejso.2001.1196","article-title":"Mucinous adenocarcinoma of the small bowel with peritoneal seeding","volume":"28","author":"Marchettini","year":"2002","journal-title":"Eur J Surg Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.cpsurg.2020.100860_bib0274","article-title":"Management of peritoneal metastases - Basic concepts","volume":"20","author":"Sugarbaker","year":"2015","journal-title":"J buon"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0275","first-page":"45","article-title":"Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy","volume":"7","author":"Goodman","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0276","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2017.10.012","article-title":"Synchronous peritoneal metastases of small bowel adenocarcinoma: Insights into an underexposed clinical phenomenon","volume":"87","author":"Legue","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_sbref0277","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jso.20296","article-title":"Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma","volume":"91","author":"Jacks","year":"2005","journal-title":"J Surg Oncol"},{"issue":"9","key":"10.1016\/j.cpsurg.2020.100860_bib0278","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/annonc\/mdq038","article-title":"Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study","volume":"21","author":"Zaanan","year":"2010","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.cpsurg.2020.100860_bib0279","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1634\/theoncologist.2012-0079","article-title":"Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy","volume":"17","author":"Tsushima","year":"2012","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0280","doi-asserted-by":"crossref","first-page":"869","DOI":"10.21037\/jgo.2019.05.02","article-title":"Survival trends of metastatic small intestinal neuroendocrine tumor: a population-based analysis of SEER database","volume":"10","author":"Shah","year":"2019","journal-title":"J Gastrointest Oncol"},{"issue":"11","key":"10.1016\/j.cpsurg.2020.100860_bib0281","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s002680010232","article-title":"Method for dissection of mesenteric metastases in mid-gut carcinoid tumors","volume":"24","author":"Ohrvall","year":"2000","journal-title":"World J Surg"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_sbref0282","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.sla.0000164073.08093.5d","article-title":"Surgical treatment of advanced-stage carcinoid tumors: lessons learned","volume":"241","author":"Boudreaux","year":"2005","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.cpsurg.2020.100860_bib0283","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00268-004-7610-2","article-title":"Long-term survival of patients with small intestinal carcinoid tumors","volume":"28","author":"Zar","year":"2004","journal-title":"World J Surg"},{"issue":"7","key":"10.1016\/j.cpsurg.2020.100860_bib0284","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00259-006-0317-x","article-title":"Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?","volume":"34","author":"Antunes","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"28","key":"10.1016\/j.cpsurg.2020.100860_bib0285","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0286","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/eje.0.1510107","article-title":"High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours","volume":"151","author":"Welin","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0287","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cncr.10195","article-title":"Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma","volume":"94","author":"Shojamanesh","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0288","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.cpsurg.2020.100860_sbref0289","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/000313480206800803","article-title":"Cytoreductive surgery in patients with advanced-stage carcinoid tumors","volume":"68","author":"Gulec","year":"2002","journal-title":"Am Surg"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0290","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000286700","article-title":"ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors","volume":"91","author":"Kianmanesh","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0291","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.surg.2013.05.030","article-title":"Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intra-abdominal metastases)","volume":"155","author":"Elias","year":"2014","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0292","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.surg.2004.11.007","article-title":"Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas","volume":"137","author":"Elias","year":"2005","journal-title":"Surgery"},{"issue":"Suppl 3","key":"10.1016\/j.cpsurg.2020.100860_bib0293","article-title":"Surgical management of small bowel neuroendocrine tumors: specific requirements and their impact on staging and prognosis","volume":"22","author":"Pasquer","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0294","doi-asserted-by":"crossref","first-page":"680126","DOI":"10.1155\/2014\/680126","article-title":"Incidence and outcomes of desmoplastic small round cell tumor: results from the surveillance, epidemiology, and end results database","volume":"2014","author":"Lettieri","year":"2014","journal-title":"J Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0295","doi-asserted-by":"crossref","first-page":"W45","DOI":"10.2214\/AJR.18.20179","article-title":"Desmoplastic small round cell tumor: imaging pattern of disease at presentation","volume":"212","author":"Morani","year":"2019","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"10.1016\/j.cpsurg.2020.100860_bib0296","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpedsurg.2007.05.047","article-title":"Continuous hyperthermic peritoneal perfusion for desmoplastic small round cell tumor","volume":"42","author":"Hayes-Jordan","year":"2007","journal-title":"J Pediatr Surg"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0297","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/pbc.24160","article-title":"Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis\/carcinomatosis: early experience and phase 1 results","volume":"59","author":"Hayes-Jordan","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0298","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1245\/s10434-018-6333-9","article-title":"Desmoplastic small round cell tumor treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results of a phase 2 trial","volume":"25","author":"Hayes-Jordan","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0299","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1245\/s10434-014-4289-y","article-title":"Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for children, adolescents, and young adults: the first 50 cases","volume":"22","author":"Hayes-Jordan","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.26934","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal perfusion with chemotherapy in children with peritoneal tumor spread: A French nationwide study over 14 years","volume":"65","author":"Scalabre","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0301","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1245\/s10434-019-07339-2","article-title":"Desmoplastic small round cell tumor: long-term complications after cytoreduction and hyperthermic intraperitoneal chemotherapy","volume":"27","author":"Stiles","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.cpsurg.2020.100860_bib0302","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jpedsurg.2017.09.014","article-title":"Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for disseminated intra-abdominal malignancies in children-a single-institution experience","volume":"53","author":"Zmora","year":"2018","journal-title":"J Pediatr Surg"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0303","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00000478-199204000-00010","article-title":"A novel reciprocal chromosome translocation t(11;22)(p13;q12) in an intraabdominal desmoplastic small round-cell tumor","volume":"16","author":"Sawyer","year":"1992","journal-title":"Am J Surg Pathol"},{"issue":"19","key":"10.1016\/j.cpsurg.2020.100860_bib0304","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1158\/1078-0432.CCR-18-0202","article-title":"Multimodality treatment of desmoplastic small round cell tumor: chemotherapy and complete cytoreductive surgery improve patient survival","volume":"24","author":"Subbiah","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0305","doi-asserted-by":"crossref","first-page":"e0171639","DOI":"10.1371\/journal.pone.0171639","article-title":"Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery?","volume":"12","author":"Honore","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0306","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1200\/JCO.1996.14.5.1526","article-title":"Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy","volume":"14","author":"Kushner","year":"1996","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0307","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1053\/j.sempedsurg.2016.09.005","article-title":"Management of desmoplastic small round cell tumor","volume":"25","author":"Hayes-Jordan","year":"2016","journal-title":"Semin Pediatr Surg"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0308","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00280-006-0280-z","article-title":"Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy","volume":"59","author":"Fine","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0309","doi-asserted-by":"crossref","first-page":"e27517","DOI":"10.1002\/pbc.27517","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A safe treatment option for intraperitoneal rhabdomyosarcoma in children below 5 years of age","volume":"66","author":"Gesche","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.cpsurg.2020.100860_bib0310","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1097\/MPH.0000000000001231","article-title":"Novel therapy for pediatric angiosarcoma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"40","author":"Winer","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"10.1016\/j.cpsurg.2020.100860_bib0311","doi-asserted-by":"crossref","first-page":"e27753","DOI":"10.1002\/pbc.27753","article-title":"Pediatric ovarian angiosarcoma treated with systemic chemotherapy and cytoreductive surgery with heated intraperitoneal chemotherapy: Case report and review of therapy","volume":"66","author":"Pariury","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0312","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00383-015-3814-9","article-title":"Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric ovarian tumors: a novel treatment approach","volume":"32","author":"Hayes-Jordan","year":"2016","journal-title":"Pediatr Surg Int"},{"issue":"11","key":"10.1016\/j.cpsurg.2020.100860_bib0313","doi-asserted-by":"crossref","first-page":"236","DOI":"10.21037\/atm.2017.03.96","article-title":"Malignant peritoneal mesothelioma: a review","volume":"5","author":"Kim","year":"2017","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0314","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.amjsurg.2014.11.004","article-title":"Treatment of carcinomatosis using cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in adolescents and young adults","volume":"209","author":"Oyeniyi","year":"2015","journal-title":"Am J Surg"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0315","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1002\/cncr.31994","article-title":"Clinical and molecular characterization of early-onset colorectal cancer","volume":"125","author":"Willauer","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0316","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jamcollsurg.2019.12.043","article-title":"Colon cancer in patients under 25 years old: a different disease?","volume":"230","author":"Hayes-Jordan","year":"2020","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0317","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijscr.2019.02.046","article-title":"Cytoreductive surgery and HIPEC in a 14 years old patient with peritoneal recurrence of adenocarcinoma of the right colon","volume":"57","author":"Sorrentino","year":"2019","journal-title":"Int J Surg Case Rep"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0318","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1517\/14712590903307370","article-title":"Modification of mammalian reoviruses for use as oncolytic agents","volume":"9","author":"Van Den Wollenberg","year":"2009","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0319","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1006\/viro.1993.1602","article-title":"Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency","volume":"197","author":"Strong","year":"1993","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.cpsurg.2020.100860_bib0320","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1172\/JCI9871","article-title":"Reovirus as a novel oncolytic agent","volume":"105","author":"Norman","year":"2000","journal-title":"J Clin Invest"},{"issue":"17","key":"10.1016\/j.cpsurg.2020.100860_bib0321","doi-asserted-by":"crossref","first-page":"8135","DOI":"10.1128\/JVI.74.17.8135-8139.2000","article-title":"Reovirus-induced apoptosis is mediated by TRAIL","volume":"74","author":"Clarke","year":"2000","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0322","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1525-0016(02)00033-3","article-title":"An oncolytic measles virus engineered to enter cells through the CD20 antigen","volume":"7","author":"Bucheit","year":"2003","journal-title":"Mol Ther: the journal of the American Society of Gene Therapy"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0323","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","article-title":"Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer","volume":"70","author":"Galanis","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0324","unstructured":"Galanis, E.MV-NIS or investigator's choice chemotherapy in treating patients with ovarian, fallopian, or peritoneal cancer. 2015 [updated December 30, 2019]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02364713."},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0325","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/hum.2006.17.31","article-title":"Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates","volume":"17","author":"Naik","year":"2006","journal-title":"Hum Gene Ther"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0326","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.cgt.7700549","article-title":"Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers","volume":"9","author":"Zeh","year":"2002","journal-title":"Cancer Gene Ther"},{"issue":"20","key":"10.1016\/j.cpsurg.2020.100860_bib0327","doi-asserted-by":"crossref","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-07-0146","article-title":"Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus","volume":"67","author":"Zhang","year":"2007","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.cpsurg.2020.100860_bib0328","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I study of oncolytic vaccinia virus gl-onc1 in patients with peritoneal carcinomatosis","volume":"24","author":"Lauer","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0329","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0330","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1128\/JVI.77.6.3768-3776.2003","article-title":"Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy","volume":"77","author":"Samady","year":"2003","journal-title":"J Virol"},{"issue":"34","key":"10.1016\/j.cpsurg.2020.100860_bib0331","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0332","first-page":"441","article-title":"Adaptive immunity in cancer immunology and therapeutics","volume":"8","author":"Spurrell","year":"2014","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0333","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.jid.5700001","article-title":"Cytotoxic T cells","volume":"126","author":"Andersen","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0334","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00428-018-2484-0","article-title":"Adoptive cellular therapies: the current landscape","volume":"474","author":"Rohaan","year":"2019","journal-title":"Virchows Arch: an international journal of pathology"},{"issue":"24","key":"10.1016\/j.cpsurg.2020.100860_bib0335","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.3390\/ijms20246223","article-title":"Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy","volume":"20","author":"Stock","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0336","doi-asserted-by":"crossref","first-page":"1700097","DOI":"10.1002\/biot.201700097","article-title":"Cancer immunotherapy using CAR-T cells: from the research bench to the assembly line","volume":"13","author":"Gomes-Silva","year":"2018","journal-title":"Biotechnol J"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0337","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"6024","key":"10.1016\/j.cpsurg.2020.100860_bib0338","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science (New York, NY)"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0339","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/ijms21020515","article-title":"Finding the keys to the CAR: identifying novel target antigens for T cell redirection immunotherapies","volume":"21","author":"Abbott","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0340","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/ijms21010204","article-title":"The evolving protein engineering in the design of chimeric antigen receptor T cells","volume":"21","author":"Hughes-Parry","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0341","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0342","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T Cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0343","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-018-0759-3","article-title":"Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0344","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0345","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/jcm9010182","article-title":"Chimeric antigen receptor T-Cell therapy for colorectal cancer","volume":"9","author":"Sur","year":"2020","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.cpsurg.2020.100860_bib0346","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000050638","article-title":"The CA 125 gene: an extracellular superstructure dominated by repeat sequences","volume":"22","author":"O'Brien","year":"2001","journal-title":"Tumour Biol : the journal of the International Society for Oncodevelopmental Biology and Medicine"},{"issue":"29","key":"10.1016\/j.cpsurg.2020.100860_bib0347","doi-asserted-by":"crossref","first-page":"27371","DOI":"10.1074\/jbc.M103554200","article-title":"Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16","volume":"276","author":"Yin","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0348","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0349","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.cpsurg.2020.100860_bib0350","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-017-2045-4","article-title":"CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target","volume":"66","author":"Holzinger","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"24","key":"10.1016\/j.cpsurg.2020.100860_bib0351","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.1158\/1078-0432.CCR-07-4910","article-title":"Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation","volume":"14","author":"Emtage","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.cpsurg.2020.100860_bib0352","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for cea+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.cpsurg.2020.100860_bib0353","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0354","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1479-5876-10-157","article-title":"A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer","volume":"10","author":"Kandalaft","year":"2012","journal-title":"J Transl Med"},{"issue":"20 Pt 1","key":"10.1016\/j.cpsurg.2020.100860_bib0355","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.cpsurg.2020.100860_bib0356","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","article-title":"In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)","volume":"71","author":"Song","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0357","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.2147\/OTT.S203550","article-title":"Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer","volume":"12","author":"Yan","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"9","key":"10.1016\/j.cpsurg.2020.100860_bib0358","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0359","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0360","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/1055-9965.EPI-11-0993","article-title":"Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma","volume":"21","author":"Rizk","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0361","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114900","article-title":"Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival","volume":"9","author":"Tozbikian","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0362","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0363","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0364","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0365","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0366","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/17474086.2019.1585238","article-title":"Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy","volume":"12","author":"Acharya","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0367","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1038\/s41467-019-10565-7","article-title":"Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters","volume":"10","author":"Lee","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0368","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/PPO.0000000000000377","article-title":"Management of T-Cell Engaging Immunotherapy Complications","volume":"25","author":"Varadarajan","year":"2019","journal-title":"Cancer J"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0369","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0370","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.cpsurg.2020.100860_bib0371","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/bjc.2017.356","article-title":"TAMeless traitors: macrophages in cancer progression and metastasis","volume":"117","author":"Aras","year":"2017","journal-title":"Br J Cancer"},{"issue":"33","key":"10.1016\/j.cpsurg.2020.100860_bib0372","doi-asserted-by":"crossref","first-page":"15578","DOI":"10.1039\/C8NR05294H","article-title":"A multi-functional macrophage and tumor targeting gene delivery system for the regulation of macrophage polarity and reversal of cancer immunoresistance","volume":"10","author":"He","year":"2018","journal-title":"Nanoscale"},{"issue":"16","key":"10.1016\/j.cpsurg.2020.100860_bib0373","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1158\/0008-5472.CAN-10-3143","article-title":"CXCL12\/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer","volume":"71","author":"Righi","year":"2011","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.cpsurg.2020.100860_bib0374","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1593\/neo.09988","article-title":"The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment","volume":"11","author":"Mizutani","year":"2009","journal-title":"Neoplasia (New York, NY)"},{"issue":"8","key":"10.1016\/j.cpsurg.2020.100860_bib0375","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","article-title":"Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling","volume":"119","author":"Hume","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0376","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ijc.23083","article-title":"Involvement of SDF-1alpha\/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma","volume":"122","author":"Kajiyama","year":"2008","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0377","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1593\/neo.111076","article-title":"Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4","volume":"13","author":"Ray","year":"2011","journal-title":"Neoplasia (New York, NY)"},{"issue":"24","key":"10.1016\/j.cpsurg.2020.100860_bib0378","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1158\/0008-5472.CAN-11-2449","article-title":"PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment","volume":"71","author":"Obermajer","year":"2011","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0379","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/1541-7786.MCR-10-0394","article-title":"S100A8\/A9 activate key genes and pathways in colon tumor progression","volume":"9","author":"Ichikawa","year":"2011","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10.1016\/j.cpsurg.2020.100860_bib0380","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cell.2012.04.042","article-title":"A CXCL1 paracrine network links cancer chemoresistance and metastasis","volume":"150","author":"Acharyya","year":"2012","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.cpsurg.2020.100860_bib0381","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/0008-5472.CAN-11-1792","article-title":"Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment","volume":"72","author":"Lesokhin","year":"2012","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.cpsurg.2020.100860_bib0382","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.4049\/jimmunol.1201161","article-title":"Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment","volume":"189","author":"Simpson","year":"2012","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"8","key":"10.1016\/j.cpsurg.2020.100860_bib0383","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/0008-5472.CAN-04-4505","article-title":"Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion","volume":"65","author":"Zea","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.cpsurg.2020.100860_bib0384","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3389\/fimmu.2018.01977","article-title":"Turn back the TIMe: targeting tumor infiltrating myeloid cells to revert cancer progression","volume":"9","author":"Awad","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.cpsurg.2020.100860_bib0385","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.immuni.2013.08.025","article-title":"Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2","volume":"39","author":"Cui","year":"2013","journal-title":"Immunity"},{"issue":"1-2","key":"10.1016\/j.cpsurg.2020.100860_bib0386","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1615\/CritRevOncog.2014010827","article-title":"Dendritic cell editing by natural killer cells","volume":"19","author":"Ferlazzo","year":"2014","journal-title":"Crit Rev Oncog"},{"issue":"11","key":"10.1016\/j.cpsurg.2020.100860_bib0387","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","article-title":"The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity","volume":"4","author":"Bottcher","year":"2018","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.cpsurg.2020.100860_bib0388","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"}],"container-title":["Current Problems in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011384020301301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011384020301301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T06:00:07Z","timestamp":1696399207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011384020301301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":388,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0011384020301301"],"URL":"https:\/\/doi.org\/10.1016\/j.cpsurg.2020.100860","relation":{},"ISSN":["0011-3840"],"issn-type":[{"value":"0011-3840","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evolving Management of Peritoneal Surface Malignancies","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpsurg.2020.100860","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100860"}}